

**Table S1.** Primers used in the study

<b>Primer</b>	<b>Nucleotide sequence (5' to 3')</b>
AmpC-C2-RT_F	GCCGCACTACTTTACCTTCG
AmpC-C2-RT_R	TACGCCGGTGAAGGTTTAC
AmpC-C3-RT_F	CAACGCCAGTATCGGTCTTT
AmpC-C3-RT_R	GCTTTCGGAACGTTAATCCA
AmpC-C4-RT_F	CGGTGGCGGTAATTTATCAG
AmpC-C4-RT_R	GTACGCCGGTGAAGGTTTTA
AmpC-C5-RT_F	ATTAACGTTCCGAAGGCAGA
AmpC-C5-RT_R	CTCGCCATATCCTTCACGTT
AmpC-C6-RT_F	GATATGGCGAACTGGGTCAT
AmpC-C6-RT_R	CAGCCCAGACCCTGATACAT
AmpC-C8-RT_F	GGCTATCGTGACGGTAAAGC
AmpC-C8-RT_R	TAAGTGAGGCATCAGCAACG
RpoB-ECC_F	AAGGCGAATCCAGCTTGTTTCAGC
RpoB-ECC_R	TGACGTTGCATGTTTCGCACCCATCA

**Table S2.** ECC strains included in the study according to their cluster memberships and phenotypes of resistance to third-generation cephalosporins

Cluster	No.	Phenotype			
		WT	ESBL alone	ESBL+HL-CASE	HL-CASE
C-I	3	2	0	0	1
C-II	4	2	0	0	2
C-III	20	4	3	4	9
C-IV	4	2	0	0	2
C-V	6	2	0	0	4
C-VI	19	3	2	10	4
C-VII	2	2	0	0	0
C-VIII	26	5	4	5	12
C-IX	2	2	0	0	0
C-X	2	2	0	0	0
C-XI	4	4	0	0	0
C-XII	2	2	0	0	0
<b>Total</b>	<b>94</b>	<b>32</b>	<b>9</b>	<b>19</b>	<b>34</b>

**Table S3.** Characteristics of ESBL-producing strains

<b><math>\beta</math>-lactamase(s) detected</b>	<b>No.</b>	<b>Cluster (no.)</b>
CTX-M-9	2	C-III (2)
TEM-15	1	C-III (1)
CTX-M-15	15	C-III (3), C-VI (10), C-VIII (2)
SHV-12	8	C-III (1), C-VIII (7)
CTX-M-15, OXA-204, CMY-4	1	C-VI (1)*
CTX-M-15, SHV-12, DHA-1	1	C-VI (1)*

\*AmpC-overproducing strains.